Abstract
The objective of the present research work is developing a gradient, reversed phase liquid chromatographic method for the determination of saxagliptin hydrochloride in bulk drugs and pharmaceutical dosage form. The chromatographic separation was achieved on a Inertsil C8 (4.6x250) mm, 5 µm column, the gradient LC method employs solution A and B as mobile phase. The solution A contains (1.20g of sodium dihydrogen phosphate in 1000 ml of water) pH 5.0 solution B (acetonitrile) at flow rate 1.2 ml/min. The UV detector was operated at 210 nm and temperature was 25˚c. The retention time was 7.68 min and linearity was observed in the concentration range of 50-375 µg/ml with correlation coefficient of 0.9999. The percentage relative standard deviation in accuracy and precision studies was found to be less than 2%. The method was successfully validated as per International Conference on Harmonization (ICH) guidelines. Saxagliptin hydrochloride undergoes degradation under acidic, basic, oxidation, dry heat and photolytic conditions, degradation impurities did not interfere with the retention time of Saxagliptin hydrochloride. The proposed method was found to be a new, simple, precise, linear, accurate, specific and stability indicating.
References
David J. Augeri , Jeffrey A. Robl , David A. Betebenner , David R. Magnin , Ashish Khanna , James G. Robertson
, Aiying Wang , Ligaya M. Simpkins , Prakash Taunk , Qi Huang , Song-Ping Han , Benoni Abboa-Offei , Michael Cap , Li Xin , Li Tao , Effie Tozzo , Gustav E. Welzel , Donald M. Egan , Jovita Marcinkeviciene , Shu Y. Chang , Scott A. Biller , Mark S. Kirby , Rex A. Parker , and Lawrence G. Hamann, Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes, J. Med. Chem., 2005, 48 (15), pp 5025– 5037.
Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26(5):488-499.
Robertson JG. Discovery and preclinical profile of saxagliptin, A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48(15): 5025- 37.
Saxagliptin: A clinical review in the treatment of type 2 diabetes mellitus, Clin Ther 2011; 33:1005-1022.
Deanna KS. Jasmine GD., Zachary WA., Kulasa K., EdelmanS. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core evidence 2010; 5:23-37.
Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a New DPP-4 Inhibitor for the treatment of Type 2 diabetes mellitus. Adv Ther 2011; 26(3): 249-262.
Carolyn DF. Jens HJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.Adv Ther 2011; 26(5): 488-499.
Hollander P., Jia L.,Allen E., Che R.. Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with type 2 diabetes and Inadequate Control on Thiazolidinedione Alone. J Clin EndocrinolMetab 2009; 94(12): 4810 -19.
Yang W.,Pan C.,Tou C.,Zhao J., Nilsson IG. Efficacy and safety of saxagliptin added to metformin in Asian patients with type 2 diabetes mellitus: A randomized controlled trial. Dia Res Clin Pra 2011; 5 3(1): 1-8.
Hess C., Musshoff F., Madea B. Simultaneous identification and validated quantification of oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography–mass spectrometry. Anal Bioanal Chem 2011; 400: 33-41.
Kalaichelvi R, Jayachandran E, Validated Spectroscopic method for the estimation of Saxagliptinin pure and from tablet formulation. Int J Pharm Pharm Sci 2011; 3: 179-180.
Narendra Nyola, Govinda Samy Jeyabalan, Development and validation of uv-vis specctroscopy method for simultaneous estimation of saxagliptin hydrochloride and metforminhydrochloride in active pharmaceutical ingrident, J Pharm Educ Res Vol. 3, Issue No. 2, December 2012.
Mohammad Abdul‐Azim Mohammad, Ehab Farouk Elkady and Marwa Ahmed Fouad, Development and validation of a reversed‐phase column liquid chromatographic method for simultaneous determination of two novel gliptins in their binary mixtures with Metformin, European Journal of Chemistry 3 (2) (2012) 152‐155.
Patil Prafulla Prakash, Kalkotwar Ramesh.S, Patil Vikas V, Jadhav Vijay.B, Patil Nilesh .P, A new RP – HPLC Method for derermination of metformin hcl and saxagliptin in tablet dosage form, IJPBS |Volume 2| Issue 4 |OCT-DEC |2012|161-167.
N.V.M.S. Bhagavanji, Development and validation of stability indicating LC method for the simultaneous estimation of metformin and saxagliptin in combined dosage form, VSRD International Journal of Technical & Non-Technical Research, Vol. 3 No. 11 November 2012.
Srikanth Inturi,Ravikanth Inturi, Israel kumar Tagaram, validated novel LC determination of saxagliptin in pure bulk and pharmaceutical dosage forms, IJPRD, 2011; Vol 3(8): November 2011 (45 - 52).
R. Pravin Cumar, M.Vasudevan and Deecaraman, A validated RP- HPLC method for simultaneous estimation of metform and saxagliptin in tablets, rjc Vol. 5 | No.2| 137-141 | April-June | 2012.
M.Sarat,P.Muralikrishna and C.Rambabu, RP-HPLC method for simultaneous estimation of sexagliptin and piolitazone in tablets, IRJP 2012,3(5).
ICH Q2 (R1), Validation of analytical procedures: Text and Methodology, Fed. Reg (19 May 1997) 62:27463.
Snyder LR, Kirkland JJ, Glajch JI. PracticalHPLC Method Development.2nd ed.; 1997.p. 2.
www.wikipedia.org/wiki/ Saxagliptin.
www.chemblink.com/products/ 709031-78-7
How to cite your article:
Chhabda P. J., Balaji M., Srinivasarao V., Ramakrishna K., Apparao K. M. Ch., “Devolpment and validation of simple stability indicating rP-HPLC method for analysis of saxagliptin and its forced degradation impurities in bulk drug and pharmaceutical dosage form”, Int. J. Res. Dev. Pharm. L. Sci., 2014, 3(3), pp. 993-1003.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array